Christian Dittrich

Christian Dittrich

UNVERIFIED PROFILE

Are you Christian Dittrich?   Register this Author

Register author
Christian Dittrich

Christian Dittrich

Publications by authors named "Christian Dittrich"

Are you Christian Dittrich?   Register this Author

69Publications

1415Reads

42Profile Views

Phase Ib trial combining capecitabine, erlotinib and bevacizumab in pancreatic adenocarcinoma - REBECA trial.

Invest New Drugs 2019 02 12;37(1):127-138. Epub 2018 Jul 12.

Division of Clinical Pharmacy, Department of Pharmaceutical Chemistry, Centre of Pharmacy, University of Vienna, Althanstrasse 14, 1090, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-018-0639-0DOI Listing
February 2019

Monitoring of erlotinib in pancreatic cancer patients during long-time administration and comparison to a physiologically based pharmacokinetic model.

Cancer Chemother Pharmacol 2018 04 16;81(4):763-771. Epub 2018 Feb 16.

Division of Clinical Pharmacy and Diagnostics, Faculty of Life Sciences, University of Vienna, Althanstrasse 14, 1090, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-018-3545-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5854746PMC
April 2018

Global Curriculum Edition 2016: European Society for Medical Oncology/American Society of Clinical Oncology Recommendations for Training in Medical Oncology.

J Clin Oncol 2017 01 31;35(2):254-255. Epub 2016 Oct 31.

Christian Dittrich, Kaiser Franz Josef-Spital, and Applied Cancer Research-Institution for Translational Research, Vienna, Austria; Michael P. Kosty, Scripps Clinic, La Jolla, CA; Svetlana Jezdic, European Society for Medical Oncology, Lugano, Switzerland; Doug Pyle, American Society of Clinical Oncology, Alexandria, VA; Rossana Berardi, Azienda Ospedaliero-Universitaria Ospedali Riuniti Università Politecnica delle Marche, Ancona, Italy; Jonas Bergh, Radiumhemmet, Karolinska Institutet and University Hospital, Stockholm, Sweden; Nagi S. El-Saghir, NK Basile Cancer Institute, American University of Beirut Medical Center, Beirut, Lebanon; Jean-Pierre Lotz, Assistance Publique-Hopitaux de Paris, Tenon Hospital, Institut Universitaire de Cancerologie-Universite Pierre et Marie Curie, Sorbonne University, Paris, France; Pia Österlund, Helsinki University Central Hospital and University of Helsinki, Helsinki, Finland; Nicholas Pavlidis, University of Ioannina, Ioannina, Greece; and Gunta Purkalne, Pauls Stradins Clinical University Hospital, Riga, Latvia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.70.2431DOI Listing
January 2017

Assessment of Pharmacokinetic Interaction Between Capecitabine and Cetuximab in Metastatic Colorectal Cancer Patients.

Anticancer Res 2016 09;36(9):4715-23

Ludwig Boltzmann Institute for Applied Cancer Research (LBI-ACR VIEnna)-LB-CTO and Applied Cancer Research-Institution for Translational Research Vienna (ACR-ITR VIEnna), Kaiser Franz Josef-Spital, 3rd Medical Department, Center for Oncology and Hematology, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.11026DOI Listing
September 2016

ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016.

Authors:
Christian Dittrich Michael Kosty Svetlana Jezdic Doug Pyle Rossana Berardi Jonas Bergh Nagi El-Saghir Jean-Pierre Lotz Pia Österlund Nicholas Pavlidis Gunta Purkalne Ahmad Awada Susana Banerjee Smita Bhatia Jan Bogaerts Jan Buckner Fatima Cardoso Paolo Casali Edward Chu Julia Lee Close Bertrand Coiffier Roisin Connolly Sarah Coupland Luigi De Petris Maria De Santis Elisabeth G E de Vries Don S Dizon Jennifer Duff Linda R Duska Alexandru Eniu Marc Ernstoff Enriqueta Felip Martin F Fey Jill Gilbert Nicolas Girard Andor W J M Glaudemans Priya K Gopalan Axel Grothey Stephen M Hahn Diana Hanna Christian Herold Jørn Herrstedt Krisztian Homicsko Dennie V Jones Lorenz Jost Ulrich Keilholz Saad Khan Alexander Kiss Claus-Henning Köhne Rainer Kunstfeld Heinz-Josef Lenz Stuart Lichtman Lisa Licitra Thomas Lion Saskia Litière Lifang Liu Patrick J Loehrer Merry Jennifer Markham Ben Markman Marius Mayerhoefer Johannes G Meran Olivier Michielin Elizabeth Charlotte Moser Giannis Mountzios Timothy Moynihan Torsten Nielsen Yuichiro Ohe Kjell Öberg Antonio Palumbo Fedro Alessandro Peccatori Michael Pfeilstöcker Chandrajit Raut Scot C Remick Mark Robson Piotr Rutkowski Roberto Salgado Lidia Schapira Eva Schernhammer Martin Schlumberger Hans-Joachim Schmoll Lowell Schnipper Cristiana Sessa Charles L Shapiro Julie Steele Cora N Sternberg Friedrich Stiefel Florian Strasser Roger Stupp Richard Sullivan Josep Tabernero Luzia Travado Marcel Verheij Emile Voest Everett Vokes Jamie Von Roenn Jeffrey S Weber Hans Wildiers Yosef Yarden

ESMO Open 2016 29;1(5):e000097. Epub 2016 Sep 29.

Department of General Medical Oncology , University Hospitals Leuven , Leuven , Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/esmoopen-2016-000097DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070299PMC
September 2016

Immune-mediated liver injury of the cancer therapeutic antibody catumaxomab targeting EpCAM, CD3 and Fcγ receptors.

Oncotarget 2016 May;7(19):28059-74

Applied Cancer Research - Institution for Translational Research Vienna (ACR-ITR VIEnna) and Ludwig Boltzmann Institute for Applied Cancer Research (LBI-ACR VIEnna), Center for Oncology and Hematology, Kaiser Franz Josef-Spital, Vienna, Austria.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5053709PMC
http://dx.doi.org/10.18632/oncotarget.8574DOI Listing
May 2016

Breast Cancer Subtypes in Patients Aged 70 Years and Older.

Cancer Invest 2016 May 23;34(5):197-204. Epub 2016 May 23.

a Ludwig Boltzmann Institute for Applied Cancer Research (LBI-ACR VIEnna)-LB Cluster Translational Oncology, 3rd Medical Department-Centre for Oncology and Haematology, Kaiser Franz Josef-Spital , Vienna , Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/07357907.2016.1182184DOI Listing
May 2016

The ESMO/ASCO Global Curriculum and the evolution of medical oncology training in Europe.

ESMO Open 2016 18;1(1):e000004. Epub 2016 Jan 18.

Ludwig Boltzmann Institute for Applied Cancer Research (LBI-ACR VIEnna) and Applied Cancer Research-Institution for Translational Research Vienna (ACR-ITR VIEnna) Centre for Oncology and Haematology Kaiser Franz Josef-Spital , Vienna , Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/esmoopen-2015-000004DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070208PMC
January 2016

A simple method for comparing enzymatic capecitabine activation in various mono- and combination chemotherapies.

Pharmacology 2015 9;95(1-2):29-31. Epub 2015 Jan 9.

Division of Clinical Pharmacy and Diagnostics, University of Vienna, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000369934DOI Listing
October 2015

A phase I trial of intravenous catumaxomab: a bispecific monoclonal antibody targeting EpCAM and the T cell coreceptor CD3.

Cancer Chemother Pharmacol 2015 May 27;75(5):1065-73. Epub 2015 Mar 27.

Department of Oncology, The Finsen Centre, Rigshospitalet, Copenhagen, Denmark,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-015-2728-5DOI Listing
May 2015

A phase 1 dose escalation study of BI 831266, an inhibitor of Aurora kinase B, in patients with advanced solid tumors.

Invest New Drugs 2015 Apr 23;33(2):409-22. Epub 2014 Dec 23.

Ludwig Boltzmann Institute for Applied Cancer Research (LBI-ACR VIEnna) - LB Cluster Translational Oncology and Applied Cancer Research-Institution for Translational Research Vienna (ACR-ITR VIEnna), Third Medical Department, Center for Oncology and Hematology, Kaiser-Franz-Josef-Spital, Vienna, Austria,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10637-014-0201-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4387274PMC
April 2015

Lapatinib-plus-pegylated liposomal doxorubicin in advanced HER2-positive breast cancer following trastuzumab: a phase II trial.

Anticancer Res 2015 Jan;35(1):517-21

3rd Medical Department with Haematology, Medical Oncology, Hemostaseology, Infectious Diseases, Rheumatology, Oncologic Centre, Salzburg Cancer Research Institute (SCRI) with the Laboratory of Immunological and Molecular Cancer Research (SCRI-LIMCR) and the Center for Clinical Cancer and Immunology Trials (SCRI-CCCIT), Paracelsus Medical University Salzburg, Salzburg, Austria

View Article

Download full-text PDF

Source
January 2015

Quantitative profiling of peptides from RNAs classified as noncoding.

Nat Commun 2014 Nov 18;5:5429. Epub 2014 Nov 18.

1] Proteomics Center, Boston Children's Hospital, Boston, Massachusetts 02115, USA [2] F.M. Kirby Neurobiology Center, Boston Children's Hospital, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncomms6429DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4416701PMC
November 2014

Impact of co-administered drugs on drug monitoring of capecitabine in patients with advanced colorectal cancer.

Anticancer Res 2014 Jul;34(7):3371-6

Department of Clinical Pharmacy and Diagnostics, University of Vienna, Vienna, Austria Austrian Society of Applied Pharmacokinetics, Vienna, Austria.

View Article

Download full-text PDF

Source
July 2014

Long-term remission of a Her2/neu positive primary breast cancer under double monoclonal antibody therapy with trastuzumab and bevacizumab.

Radiol Oncol 2014 Jun 25;48(2):184-8. Epub 2014 Apr 25.

Ludwig Boltzmann Institute for Applied Cancer Research (LBI-ACR VIEnna) - LB Cluster Translational Oncology, 3 Medical Department - Centre for Oncology and Haematology, Kaiser Franz Josef-Spital, Vienna, Austria ; Applied Cancer Research - Institution for Translational Research Vienna (ACR -ITR VIEnna), Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2478/raon-2013-0083DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4078037PMC
June 2014

The changing world of drug development.

Chin Clin Oncol 2014 Jun;3(2):12

Ludwig Boltzmann Institute for Applied Cancer Research-LB Cluster Translational Oncology, Center for Oncology and Hematology, Kaiser Franz Josef-Spital, Vienna, Austria; European Organisation for Research and Treatment of Cancer (EORTC)-New Drug Advisory Committee (NDAC), Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2304-3865.2014.05.12DOI Listing
June 2014

Nicotine affects pancreatic cell proteomics across species.

Proteomics 2013 May;13(9):1379-80

Merck Millipore, Schaffhausen, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pmic.201300092DOI Listing
May 2013

Validation of a simple assay for the quantification of the capecitabine metabolites 5'-DFCR and 5'-DFUR for drug monitoring in patients receiving outpatient chemotherapy.

Anticancer Res 2013 Mar;33(3):881-6

Department of Clinical Pharmacy and Diagnostics, Faculty of Life Sciences, University of Vienna, Althanstrasse 14, A-1090 Vienna, Austria.

View Article

Download full-text PDF

Source
March 2013

Tumor characteristics and recurrence patterns in triple negative breast cancer: a comparison between younger (<65) and elderly (≥65) patients.

Eur J Cancer 2012 Nov 28;48(16):2962-8. Epub 2012 May 28.

Applied Cancer Research - Institution for Translational Research Vienna, Bernardgasse 24, A-1070 Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2012.04.019DOI Listing
November 2012

How transferable are recommendations of the era of treating conventionally defined breast cancer for the era of molecularly characterised breast cancer?

Gland Surg 2012 Nov;1(3):156-8

1 Ludwig Boltzmann Institute for Applied Cancer Research (LBI-ACR VIEnna) - LB Cluster Translational Oncology, 3rd Medical Department - Centre for Oncology and Haematology, Kaiser Franz Josef-Spital, Kundratstr 3, Vienna, Austria ; 2 Applied Cancer Research - Institution for Translational Research Vienna (ACR-ITR VIEnna), Bernardgasse 24, A-1070, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3978/j.issn.2227-684X.2012.10.02DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4115702PMC
November 2012

Clinical and economic aspects of KRAS mutational status as predictor for epidermal growth factor receptor inhibitor therapy in metastatic colorectal cancer patients.

Oncology 2011 13;81(5-6):359-64. Epub 2012 Jan 13.

Ludwig Boltzmann Institute for Applied Cancer Research (LBI-ACR VIEnna), LB Cluster Translational Oncology, 3rd Medical Department, Centre for Oncology and Haematology, Kaiser Franz Josef-Spital, Vienna, Austria.

View Article

Download full-text PDF

Source
https://www.karger.com/Article/FullText/334919
Publisher Site
http://dx.doi.org/10.1159/000334919DOI Listing
June 2012

General oncology and neurological complications.

Handb Clin Neurol 2012 ;105:677-81

Third Medical Department, Center for Oncology and Hematology, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/B978-0-444-53502-3.00017-3DOI Listing
April 2012

Delivery of membrane impermeable cargo into CHO cells by peptide nanoparticles targeted by a protein corona.

Biomaterials 2012 Mar 9;33(9):2746-53. Epub 2012 Jan 9.

Dept. of Cell Biology, Harvard Medical School, 240 Longwood Avenue, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.biomaterials.2011.12.016DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3480320PMC
March 2012

Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients.

Acta Oncol 2011 Jun 24;50(5):700-10. Epub 2011 Jan 24.

Applied Cancer Research - Institution for Translational Research Vienna/CEADDP, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/0284186X.2010.549151DOI Listing
June 2011

Drug delivery vehicles with improved encapsulation efficiency: taking advantage of specific drug-carrier interactions.

Expert Opin Drug Deliv 2011 Mar 16;8(3):329-42. Epub 2011 Feb 16.

Unilever R&D Port Sunlight, Bebington, Wirral CH63 3JW, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/17425247.2011.553216DOI Listing
March 2011

Solid peptide nanoparticles--structural characterization and quantification of cargo encapsulation.

Macromol Biosci 2010 Dec;10(12):1406-15

Department of Chemistry, University of Basel, Klingelbergstrasse 80, 4056 Basel, Switzerland.

View Article

Download full-text PDF

Source
December 2010

Circulating tumor cells in metastatic colorectal cancer: efficacy and feasibility of different enrichment methods.

Cancer Lett 2010 Jul 18;293(1):117-23. Epub 2010 Feb 18.

Applied Cancer Research - Institution for Translational Research Vienna (ACR-ITR Vienna)/CEADDP, Vienna, Austria.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03043835100001
Publisher Site
http://dx.doi.org/10.1016/j.canlet.2010.01.003DOI Listing
July 2010

Pharmacokinetics of a novel anticancer ruthenium complex (KP1019, FFC14A) in a phase I dose-escalation study.

Anticancer Drugs 2009 Feb;20(2):97-103

Department of Clinical Pharmacy, Institute of Pharmacy, University of Bonn, An der Immenburg 4, Bonn, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CAD.0b013e328322fbc5DOI Listing
February 2009

Population pharmacokinetic and pharmacodynamic analysis to support treatment optimization of combination chemotherapy with indisulam and carboplatin.

Br J Clin Pharmacol 2008 Oct 29;66(4):485-97. Epub 2008 May 29.

Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute/Slotervaart Hospital, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1365-2125.2008.03230.xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2561111PMC
October 2008

Cell cycle dysregulation influences survival in high risk breast cancer patients.

Cancer Invest 2008 Aug;26(7):734-40

Third Medical Department, Centre for Oncology and Hematology, CEADDP, Applied Cancer Research, Institution for Translational Research Vienna, and Ludwig Boltzmann-Institute for Applied Cancer Research, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/07357900801944864DOI Listing
August 2008

[Principles and practice of clinical phase II studies].

Onkologie 2008 18;31 Suppl 2:46-52. Epub 2008 Apr 18.

Angewandte Krebsforschung - Institution für Translationale Forschung Wien (ACR-ITR VIEnna), Central European Anticancer Drug Development Platform, Wien, Osterreich.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000113031DOI Listing
July 2008

A phase II trial of docetaxel (Taxotere) as second-line chemotherapy in patients with metastatic breast cancer.

J Cancer Res Clin Oncol 2008 Feb 17;134(2):125-35. Epub 2007 Jul 17.

Applied Cancer Research-Institution for Translational Research Vienna (ACR-ITR VIEnna), Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00432-007-0259-0DOI Listing
February 2008

Pharmacokinetics of oxaliplatin in patients with severe hepatic dysfunction.

Cancer Chemother Pharmacol 2008 Jan 30;61(1):97-104. Epub 2007 Mar 30.

Applied Cancer Research-Institution for Translational Research Vienna (ACR-ITR VIEnna), Vienna, Austria.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00280-007-0452-5
Publisher Site
http://dx.doi.org/10.1007/s00280-007-0452-5DOI Listing
January 2008

Clinical complete long-term remission of a patient with metastatic malignant melanoma under therapy with indisulam (E7070).

Melanoma Res 2007 Oct;17(5):329-31

Applied Cancer Research-Institution for Translational Research Vienna (ACR-ITR VIEnna), Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0b013e3282ef4189DOI Listing
October 2007

A phase I study of pemetrexed (ALIMTA) and cyclophosphamide in patients with locally advanced or metastatic breast cancer.

Clin Cancer Res 2006 Dec;12(23):7071-8

Ludwig Boltzmann Institute for Applied Cancer Research and Applied Cancer Research-Institution for Translational Research Vienna, Kaiser Franz Josef-Spital, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-05-2829DOI Listing
December 2006

Use of pemetrexed in breast cancer.

Semin Oncol 2006 Jun;33(3 Suppl 9):S24-8

Applied Cancer Research -- Institution for Translational Research Vienna (ACR-ITR VIEnna), Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2006.03.017DOI Listing
June 2006

Ifosfamide/mesna as salvage therapy in platinum pretreated ovarian cancer patients--long-term results of a phase II study.

Cancer Invest 2006 Feb;24(1):22-7

Ludwig Boltzmann-Institute for Applied Cancer Research, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/07357900500449595DOI Listing
February 2006

FDG PET is superior to CT in the prediction of viable tumour in post-chemotherapy seminoma residuals.

Eur J Radiol 2005 May;54(2):284-8

Department of Nuclear Medicine, Ludwig Boltzmann Institute for Nuclear Medicine, University of Vienna, Währinger Gürtel 18-20, Vienna A-1090, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejrad.2004.07.012DOI Listing
May 2005

Overview of phase I/II pemetrexed studies.

Oncology (Williston Park) 2004 Nov;18(13 Suppl 8):18-25

AK St. Georg, Department of Medicine, Hamburg, Germany.

View Article

Download full-text PDF

Source
November 2004

Phase I and pharmacokinetic study of E7070, a chloroindolyl-sulfonamide anticancer agent, administered on a weekly schedule to patients with solid tumors.

Clin Cancer Res 2003 Nov;9(14):5195-204

Ludwig Boltmann-Institute for Applied Cancer Research, Third Medical Department with Oncology, Kaiser Franz Josef-Spital, Vienna, Austria.

View Article

Download full-text PDF

Source
November 2003

[Epidemiological studies for evaluating the role of cyclooxygenase in chemoprevention of malignant tumors].

Wien Med Wochenschr 2003 ;153(5-6):104-15

Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
September 2003

Chemoembolization with cisplatin, lipiodol and Gelfoam and subsequent systemic chemotherapy with cisplatin and interferon in patients with hepatocellular carcinoma: a non-randomized prospective study.

Int J Oncol 2003 Sep;23(3):811-9

Ludwig Boltzmann Institute for Applied Cancer Research (LBI-ACR VIEnna), 3rd Medical Department of Oncology, Kaiser Franz Josef-Spital, Kundratstrasse 3, 1100-Vienna, Austria.

View Article

Download full-text PDF

Source
September 2003

Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancer.

Invest New Drugs 2003 Aug;21(3):347-52

Ludwig Boltzmann-Institute for Applied Cancer Research (LBI-ACR VIEnna), Kaiser Franz Josef-Spital, Vienna, Austria.

View Article

Download full-text PDF

Source
August 2003

Docetaxel/cisplatin as first-line chemotherapy in patients with head and neck carcinoma: a phase II trial.

Cancer 2002 Jun;94(11):2953-8

Ludwig Boltzmann-Institute for Applied Cancer Research (LBI-ACR VIEnna), 3rd Medical Department-Oncology, Kaiser Franz Josef-Spital, Kundratstrasse, Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.10574DOI Listing
June 2002

Introducing ifosfamide in innovative treatment modalities.

Cancer Chemother Pharmacol 2002 May 16;49 Suppl 1:S1-3. Epub 2002 Apr 16.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00280-002-0444-4DOI Listing
May 2002